ROS1 and non-small cell lung carcinoma: Advanced NSCLC harboring either ALK or ROS1 fusion can be effectively treated with tyrosine kinase inhibitors (TKIs) targeting ALK or ROS1, respectively, and several ALK/ROS1 tyrosine kinase inhibitors (TKIs) are now approved by the United States Food and Drug Administration.